Neurocrine Biosciences (NBIX) Misses Q3 EPS by 8c, Revenues Beat

Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.56, $0.08 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $222.09 million versus the consensus estimate of $211.63 million.

"We are pleased that a record number of new patients initiated treatment with INGREZZA as healthcare providers continue to recognize and treat the involuntary movements associated with tardive dyskinesia," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "Our development programs continue to progress including engagement with regulatory agencies on the adult CAH pivotal trial design. We remain focused on providing patients with access to INGREZZA and preparing for the approval of opicapone in the U.S., while investing strategically to position the company as a leading global biopharmaceutical organization."

Updated 2019 SG&A and R&D Expense Guidance

SG&A, IPR&D, and R&D expenses for 2019 are expected to be $658 million to $668 million. Ongoing SG&A and R&D expenses for 2019, excluding IPR&D, are now expected to approximate $540 million to $550 million, which compares to the prior SG&A and R&D expense guidance of $540 million to $570 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Optimum Communications gets NYSE non-compliance notice over stock price